Due to the evolving COVID-19 situation, NPIN may not have the most up-to-date organization changes to services or hours. Please call the organization or visit their website to find out about any changes. This site does not have information about where to get tested for COVID-19. For COVID-19 information please visit: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
Debido a la rápida evolución de la situación con respecto al COVID-19, NPIN podría no tener la información mas actualizada de los servicios u horas de las organizaciones. Por favor llame o visite la página web de la organización para conocer los cambios. Este sitio no tiene información sobre donde hacerse la prueba del COVID-19. Para información sobre el COVID-19 por favor visite: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
Recent technical advancements have enabled generating human cell-mice chimeric brains by engrafting human iPSC-derived primitive neural progenitor cells and/or cord blood-derived microglial progenitor cells into neonatal mouse. In the chimeric brain, human neural progenitor cells or microglial cells differentiate, migrate, and distribute throughout the mouse brain. They are eventually functionally integrated into various brain regions. Such successes provide opportunities to define the structure, function, genetics and plasticity of functional neural networks containing human cells.
The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.
The purpose of this funding announcement is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators who are within 10 years of their terminal degree or residency training but who have at least two years of postdoctoral experience. The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these Early Stage Investigators to develop new research directions and to position these researchers to be competitive for new research project (e.g., R01) funding.
The purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as preclinical models.
Funding Opportunity Announcement (FOA) is soliciting applications to support research on HIV cure in pediatric populations. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. The cure of HIV infection in people living with HIV (PLWH) is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported.
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research designed to optimize smoking cessation treatment among people living with HIV (PLWH) in the United States (U.S.). Responsive applications must propose research that will be conducted with PLWH and will inform efforts to reduce the incidence of tobacco-related disease and death among PLWH.
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research designed to optimize smoking cessation treatment among people living with HIV (PLWH) in the United States (U.S.). Responsive applications must propose research that will be conducted with PLWH and will inform efforts to reduce the incidence of tobacco-related morbidity and mortality among PLWH.
This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders.